Table 1 Summary of clinicopathologic features
All carcinomas (n=106) | |
|---|---|
Age (years, median, mean±s.e.m.) | 57.5 (58.3±1.0) |
Tumor size (cm, median, mean±s.e.m.) | 1.2 (1.4±0.1) |
Menopausal status (%) | |
Premenopausal | 37 (35) |
Postmenopausal | 69 (65) |
Histologic type (%) | |
Ductal (NST) | 72 (67) |
Lobular | 4 (4) |
Tubular | 22 (21) |
Cribriform | 4 (4) |
Mucinous | 4 (4) |
Tubule formation (%) | |
1 | 30 (28) |
2 | 71 (67) |
3 | 5 (5) |
Nuclear pleomorphism (%) | |
1 | 20 (19) |
2 | 85 (80) |
3 | 1 (1) |
Mitotic activity (%) | |
1 | 106 (100) |
2 | 0 (0) |
3 | 0 (0) |
Number of mitoses per 10 HPF (median, mean±s.e.m.) | 1 (1.8±0.2) |
Lymphatic invasion (%) | |
Absent | 104 (9) |
Present | 2 (2) |
pN stage (%) | |
0(i−) | 93 (87) |
0(i+) | 5 (5) |
1mi/1a | 8 (8) |
Percent ER reactivity (median, mean±s.e.m.) | 100 (95.1±0.8) |
ER H-score (median, mean±s.e.m.) | 295 (276.8±3.3) |
Percent PR reactivity (median, mean±s.e.m.) | 85 (75.6±2.7) |
PR H-score (median, mean±s.e.m.) | 222.5 (203.0±8.7) |
HER2 status (%) | |
Negative | 106 (100) |
Positive | 0 (0.0) |
Cellular stroma (%) | |
Absent | 72 (68) |
Present | 34 (32) |
Inflammatory cells (%) | |
Absent | 78 (74) |
Present | 28 (26) |
